Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells' natural protein-denaturing machinery to ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Screening tests are critical in early detection because they can find cancer before symptoms appear, when treatment is more ...

Pfizer and Arvinas have shared promising top-line results from a late-stage study of their investigational protein degrader vepdegestrant in a subset of breast cancer patients. The phase 3 VERITAC-2 ...

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...